Alector (ALEC) Competitors

Alector (NASDAQ:ALEC) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, media sentiment, profitability and dividends.

Do analysts prefer ALEC or CCCC?

Alector currently has a consensus target price of $20.67, indicating a potential upside of 468.55%. C4 Therapeutics has a consensus target price of $10.00, indicating a potential upside of 146.91%. Given Alector's stronger consensus rating and higher possible upside, equities research analysts clearly believe Alector is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
C4 Therapeutics	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Which has more volatility and risk, ALEC or CCCC?

Alector has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 3.04, suggesting that its share price is 204% more volatile than the S&P 500.

Is ALEC or CCCC more profitable?

Alector has a net margin of -257.54% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-257.54%	-108.77%	-27.03%
C4 Therapeutics	-313.35%	-42.45%	-27.55%

Does the MarketBeat Community believe in ALEC or CCCC?

Alector received 126 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 61.54% of users gave Alector an outperform vote while only 38.24% of users gave C4 Therapeutics an outperform vote.

Company	Underperform	Outperform
Alector	Outperform Votes 152 61.54%	Underperform Votes 95 38.46%
C4 Therapeutics	Outperform Votes 26 38.24%	Underperform Votes 42 61.76%

Which has stronger valuation & earnings, ALEC or CCCC?

Alector has higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$97.06M	3.67	-$130.39M	-$1.70	-2.14
C4 Therapeutics	$20.76M	13.77	-$132.49M	-$1.70	-2.38

Does the media refer more to ALEC or CCCC?

In the previous week, C4 Therapeutics had 5 more articles in the media than Alector. MarketBeat recorded 7 mentions for C4 Therapeutics and 2 mentions for Alector. Alector's average media sentiment score of 1.05 beat C4 Therapeutics' score of 0.57 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of ALEC or CCCC?

85.8% of Alector shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 9.1% of Alector shares are held by insiders. Comparatively, 8.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Alector beats C4 Therapeutics on 13 of the 17 factors compared between the two stocks.